Genetic analysis of MC1R variants in Chinese Han patients with sporadic Parkinson's disease

Neuroscience Letters

Volumn 611, Issue , 2016, Pages 101-105

  He, Sihan ^a   Tan, Ting ^a   Song, Zhi ^a   Yuan, Lamei ^a   Deng, Xiong ^a   Ni, Bin ^b   Chen, Yong ^b   Deng, Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Family Planning Institute of Hunan Province   (China)

Author keywords

Chinese Han; MC1R gene; rs3212366; rs33932559; rs34090186; Sporadic Parkinson's disease

Indexed keywords

MELANOCORTIN 1 RECEPTOR;

ADULT; AGED; ALLELISM; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; GENETIC ASSOCIATION STUDY; GENETIC VARIATION; GENETICS; MIDDLE AGED;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTOR, MELANOCORTIN, TYPE 1;

EID: 84949267072     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.11.034     Document Type: Article

References (40)

1. Elincx-Benizri S., Inzelberg R., Greenbaum L., Cohen O.S., Yahalom G., Laitman Y., Djaldetti R., Orlev Y., Scope A., Azizi E., Friedman E., Hassin-Baer S. The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma. J. Mol. Neurosci. 2014, 54:820-825.
2. Pan T., Li X., Jankovic J. The association between Parkinson's disease and melanoma. Int. J. Cancer 2011, 128:2251-2260.
3. Bajaj A., Driver J.A., Schernhammer E.S. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010, 21:697-707.
4. Driver J.A. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology 2014, 15:547-557.
5. Dong J., Gao J., Nalls M., Gao X., Huang X., Han J., Singleton A.B., Chen H. Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol. Aging 2014, 35:1512-1515.
6. Constantinescu R., Elm J., Auinger P., Sharma S., Augustine E.F., Khadim L., Kieburtz K. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov. Disord. 2014, 29:263-265.
7. Meng S., Song F., Chen H., Gao X., Amos C.I., Lee J.E., Wei Q., Qureshi A.A., Han J. No association between Parkinson disease alleles and the risk of melanoma. Cancer Epidemiol. Biomark. Prev. 2012, 21:243-245.
8. Liu R., Gao X., Lu Y., Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76:2002-2009.
9. Bertoni J.M., Arlette J.P., Fernandez H.H., Fitzer-Attas C., Frei K., Hassan M.N., Isaacson S.H., Lew M.F., Molho E., Ondo W.G., Phillips T.J., Singer C., Sutton J.P., Wolf J.J. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch. Neurol. 2010, 67:347-352.
10. Gao X., Simon K.C., Han J., Schwarzschild M.A., Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann. Neurol. 2009, 65:76-82.
11. Gao X., Simon K.C., Han J., Schwarzschild M.A., Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology 2009, 73:1286-1291.
12. Puig-Butille J.A., Carrera C., Kumar R., Garcia-Casado Z., Badenas C., Aguilera P., Malvehy J., Nagore E., Puig S. Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. Br. J. Dermatol. 2013, 169:804-811.
13. Raimondi S., Sera F., Gandini S., Iodice S., Caini S., Maisonneuve P., Fargnoli M.C. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int. J. Cancer 2008, 122:2753-2760.
14. Pasquali E., Garcia-Borron J.C., Fargnoli M.C., Gandini S., Maisonneuve P., Bagnardi V., Specchia C., Liu F., Kayser M., Nijsten T., Nagore E., Kumar R., Hansson J., Kanetsky P.A., Ghiorzo P., Debniak T., Branicki W., Gruis N.A., Han J., Dwyer T., Blizzard L., Landi M.T., Palmieri G., Ribas G., Stratigos A., Council M.L., Autier P., Little J., Newton-Bishop J., Sera F., Raimondi S. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int. J. Cancer 2015, 136:618-631.
15. Garcia-Borron J.C., Sanchez-Laorden B.L., Jimenez-Cervantes C. Melanocortin-1 receptor structure and functional regulation. Pigm. Cell Res. 2005, 18:393-410.
16. Tell-Marti G., Puig-Butille J.A., Potrony M., Badenas C., Mila M., Malvehy J., Marti M.J., Ezquerra M., Fernandez-Santiago R., Puig S. The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann. Neurol. 2015, 77:889-894.
17. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
18. Deng H., Xu H., Deng X., Song Z., Zheng W., Gao K., Fan X., Tang J. VPS35 mutation in Chinese Han patients with late-onset Parkinson's disease. Eur. J. Neurol. 2012, 19:e96-e97.
19. Xiu X., Song Z., Gao K., Deng X., Qi Y., Zhu A., Gong L., Deng H. Genetic analysis of the FBXO48 gene in Chinese Han patients with Parkinson disease. Neurosci. Lett. 2013, 541:224-226.
20. Yuan L., Song Z., Xu H., Gu S., Zhu A., Gong L., Zhao Y., Deng H. EIF4G1 Ala502Val and Arg1205His variants in Chinese patients with Parkinson disease. Neurosci. Lett. 2013, 543:69-71.
21. Guo Y., Yang H., Deng X., Song Z., Yang Z., Xiong W., Yuan L., Xu H., Deng S., Deng H. Genetic analysis of the S100B gene in Chinese patients with Parkinson disease. Neurosci. Lett. 2013, 555:134-136.
22. Yuan L., Deng X., Song Z., Yang Z., Ni B., Chen Y., Deng H. Genetic analysis of the RAB39B gene in Chinese Han patients with Parkinson's disease. Neurobiol. Aging 2015, 36:2907-2911.
23. Guo Y., Tan T., Deng X., Song Z., Yang Z., Yang Y., Deng H. TCEANC2 rs10788972 and rs12046178 variants in the PARK10 region in Chinese Han patients with sporadic Parkinson's disease. Neurobiol. Aging 2015, 36. 10.1016/j.neurobiolaging.2015.09.002.
24. Hu J., Ng P.C. SIFT Indel: predictions for the functional effects of amino acid insertions/deletions in proteins. PLoS One 2013, 8:e77940.
25. Adzhubei I., Jordan D.M., Sunyaev S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 2015, 20. (chapter 7: unit 7.20).
26. Foo J.N., Zhao Y., Liu J., Tan E.K. Nonsynonymous variants in MC1R are rare in Chinese Parkinson disease cases. Ann. Neurol. 2015, 78:152-153.
27. Buetow K.H., Edmonson M., MacDonald R., Clifford R., Yip P., Kelley J., Little D.P., Strausberg R., Koester H., Cantor C.R., Braun A. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:581-584.
28. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15:97-98.
29. Li Z., Zhang Z., He Z., Tang W., Li T., Zeng Z., He L., Shi Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009, 19:519-523.
30. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
31. Valadas J.S., Vos M., Verstreken P. Therapeutic strategies in Parkinson's disease: what we have learned from animal models. Ann. N. Y. Acad. Sci. 2015, 1338:16-37.
32. Powers K.M., Kay D.M., Factor S.A., Zabetian C.P., Higgins D.S., Samii A., Nutt J.G., Griffith A., Leis B., Roberts J.W., Martinez E.D., Montimurro J.S., Checkoway H., Payami H. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov. Disord. 2008, 23:88-95.
33. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005, 58:963-967.
34. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
35. Deng H., Yuan L. Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res. Rev. 2014, 15:161-176.
36. Gerstenblith M.R., Goldstein A.M., Fargnoli M.C., Peris K., Landi M.T. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum. Mutat. 2007, 28:495-505.
37. Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci. 2008, 31:353-360.
38. Xia Y., Wikberg J.E., Chhajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 1995, 6:2193-2196.
39. Partridge J.M., Weatherby S.J., Woolmore J.A., Highland D.J., Fryer A.A., Mann C.L., Boggild M.D., Ollier W.E., Strange R.C., Hawkins C.P. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology 2004, 62:2323-2325.
40. Holmes D. The cancer that rises with the sun. Nature 2014, 515:S110-S111.